Q4 2025 Ascendis Pharma A/S Earnings Call Transcript
Key Points
- Ascendis Pharma AS (ASND) reported strong financial performance with a significant increase in revenue, reaching EUR 720 million for the full year 2025.
- The company achieved regulatory approvals for its TransCon Growth Hormone and TransCon PTH in both the US and Europe, expanding its market presence.
- YORVIPATH, a key product, showed robust growth with EUR 477 million in revenue for 2025, highlighting strong demand and successful market penetration.
- Ascendis Pharma AS (ASND) is on track to achieve its Vision 2030 goals, aiming for EUR 5 billion in annual product revenue by 2030.
- The company is expanding its global reach, with plans to launch products in 10 additional countries in 2026, enhancing its international market footprint.
- The insurance approval rate for YORVIPATH in the US is currently at 70%, indicating room for improvement in patient access.
- The company faces challenges in achieving 100% insurance coverage for its products, which could impact market penetration.
- There is uncertainty regarding the approval and launch timeline for TransCon CNP, which could affect future revenue projections.
- Ascendis Pharma AS (ASND) is experiencing foreign currency impacts, with the weaker US dollar negatively affecting revenue by approximately EUR 36 million in 2025.
- The competitive landscape for hypoparathyroidism and growth disorders is intensifying, with emerging agents potentially impacting market share.
Thank you for standing by and welcome to the Ascendis Pharma fourth-quarter 2025 earnings conference call. (Operator Instructions)
As a reminder, today's program is being recorded. And now I'd like to introduce your host for today's program, Chad Fugere, Vice President of Investor Relations. Please go ahead, sir.
/-
Thank you, operator, and thank you, everyone, for joining our full year 2025 financial results conference call. I'm Chad Fugere, Vice President of Investor Relations at Ascendis Pharma. Joining me on the call today are Jan Mikkelsen, President and Chief Executive Officer; Scott Smith, Chief Financial Officer; Sherrie Glass, Chief Business Officer; Jay Wu, Executive Vice President and President Ascendis US; and Amy Xu, Chief Medical Officer.
Before we begin, I would like to remind you that this conference call will contain forward-looking statements that are intended to be covered under the safe harbor provided by the Private
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
